Alvogen‘s global operations includes five manufacturing facilities in the U.S., Romania, South Korea and Taiwan. Capabilities include finished dosage form manufacturing including solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables. The company also has biosimilar capabilities via its sister company, Alvotech, in a state-of-the-art manufacturing facility in Iceland.